

AMENDMENTS TO THE CLAIMS

Claims 4 and 6-20 are withdrawn without prejudice. Claims 2 and 22 are canceled without prejudice and new claims 23, 24, and 25 have been added. Amendments to the claims are made without prejudice, and Applicants reserve the right to pursue the claims as originally filed in this or future applications. No new matter has been introduced by these amendments to the claims.

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. **(Currently amended)** A method of inhibiting unwanted cell proliferation comprising, determining whether cells overexpress a ~~gli~~ gli-1 gene, and contacting cells that overexpress a ~~gli~~ gli-1 gene with an effective amount of a ~~hedgehog antagonist~~ a hedgehog antibody; whereby said ~~antagonist~~ hedgehog antibody causes decreased cell proliferation.
2. **(Canceled)**
3. **(Currently amended)** A The method of claim 1, wherein said unwanted cell proliferation is cancer.
4. **(Withdrawn)** A method of claim 3, wherein said cancer is urogenital cancer.
5. **(Currently amended)** A The method of claim 3, wherein said cancer is associated with one or more of lung, prostate, breast, bladder, and colon tissues.
6. **(Withdrawn)** A method of claim 5, wherein said form of cancer associated with breast tissue is selected from inferior ductal carcinoma, inferior lobular carcinoma, intraductal carcinoma, medullary carcinoma and tubular carcinoma.

7. **(Withdrawn)** A method of claim 5, wherein said cancer associated with lung tissue is selected from adenocarcinoma, broncho-alveolar adenocarcinoma and small cell carcinoma.
8. **(Withdrawn)** A method of claim 5, wherein said cancer associated with the prostate is adenocarcinoma.
9. **(Withdrawn)** A method of claim 1, wherein said unwanted cell proliferation is benign prostatic hyperplasia.
10. **(Withdrawn)** A method for determining a treatment protocol comprising, obtaining a tissue sample from a patient, and determining levels of *gli* gene expression in said sample, wherein overexpression of a *gli* gene indicates that treatment with a hedgehog antagonist is appropriate.
11. **(Withdrawn)** A method of claim 10, wherein said *gli* gene is *gli-1*.
12. **(Withdrawn)** A method of claim 11, wherein *gli-1* expression levels are determined by measuring *gli-1* transcript levels.
13. **(Withdrawn)** A method of claim 11, wherein said *gli-1* levels are determined by measuring *gli-1* protein levels.
14. **(Withdrawn)** A method of stimulating surfactant production in a lung cell comprising contacting said cell with an amount of *hedgehog* antagonist effective to stimulate surfactant production.
15. **(Withdrawn)** A method of stimulating lamellated body formation in a lung cell comprising contacting said cell with an amount of *hedgehog* antagonist effective to stimulate lamellated body formation.

16. **(Withdrawn)** A method of claim 14 or 15, wherein said lung cell is present in the lung tissue of a premature infant.
17. **(Withdrawn)** A method of any one of claims 1-15, wherein said *hedgehog* antagonist is selected from a small molecule having a molecular weight less than 2000 daltons, a *hedgehog* antibody, a *patched* antibody, a *smoothened* antibody, a mutant *hedgehog* protein, an antisense nucleic acid, and a ribozyme.
18. **(Withdrawn)** A method of claim 17, wherein said small molecule is selected from cyclopamine, compound A, tomatidine, jervine, AY9944, triparanol, compound B and functionally effective derivatives thereof.
19. **(Withdrawn)** A method of determining the likelihood that a cancer will develop in a tissue, comprising
obtaining a tissue sample, and
determining levels of *gli* gene expression in said sample,
wherein overexpression of a *gli* gene indicates an increased likelihood that cancer will develop.
20. **(Withdrawn)** A method of claim 19, wherein said *gli* gene is *gli-1*.
21. **(Currently amended)** A method for treating a tumor in a patient, comprising determining whether the tumor overexpresses a *gli-1* gene and administering to said patient an amount of a ~~hedgehog~~ antagonist a hedgehog antibody sufficient to decrease the ~~grow~~ growth and/or proliferation of the tumor, wherein the tumor overexpresses a *gli-1* gene and wherein the tumor is associated with at least one of urogenital, lung, breast, prostate, bladder, or colon cancer.
22. **(Canceled)**

23. **(New)** The method of claim 3, wherein said cancer is associated with one or more of prostate, breast, bladder, and colon tissues.
24. **(New)** The method of claim 3, wherein said cancer is associated with colon tissues.
25. **(New)** The method of claim 21, wherein said tumor is associated with at least one of urogenital, breast, prostate, bladder, or colon tissues.